Clinical Trials
5 trialsNCT03402880 2026-05-29
ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer
City of Hope Medical Center
Phase 2 Withdrawn
NCT03260894 2026-05-22
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
Phase 3 Completed
NCT03414229 2026-04-23
A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT01604889 2026-04-21
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Incyte Corporation
Phase 1/2 Terminated
NCT02298153 2026-04-20
A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma
Incyte Corporation
Phase 1 Terminated